Chesley Taft & Associates LLC boosted its position in Celgene Corporation (NASDAQ:CELG) by 0.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 181,360 shares of the biopharmaceutical company’s stock after acquiring an additional 1,389 shares during the period. Celgene Corporation accounts for 2.1% of Chesley Taft & Associates LLC’s portfolio, making the stock its 6th largest position. Chesley Taft & Associates LLC’s holdings in Celgene Corporation were worth $23,553,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of CELG. Waldron LP boosted its holdings in Celgene Corporation by 48.9% in the first quarter. Waldron LP now owns 5,207 shares of the biopharmaceutical company’s stock valued at $640,000 after acquiring an additional 1,709 shares during the last quarter. 1ST Source Bank boosted its holdings in Celgene Corporation by 0.5% during the first quarter. 1ST Source Bank now owns 12,173 shares of the biopharmaceutical company’s stock worth $1,515,000 after buying an additional 65 shares during the last quarter. Narwhal Capital Management boosted its holdings in Celgene Corporation by 9.0% during the first quarter. Narwhal Capital Management now owns 6,340 shares of the biopharmaceutical company’s stock worth $789,000 after buying an additional 525 shares during the last quarter. David R. Rahn & Associates Inc. boosted its holdings in Celgene Corporation by 10.0% during the first quarter. David R. Rahn & Associates Inc. now owns 18,407 shares of the biopharmaceutical company’s stock worth $2,290,000 after buying an additional 1,668 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in Celgene Corporation by 24.1% during the first quarter. Russell Investments Group Ltd. now owns 587,487 shares of the biopharmaceutical company’s stock worth $73,108,000 after buying an additional 114,164 shares during the last quarter. Institutional investors and hedge funds own 79.33% of the company’s stock.

In other news, Director Michael D. Casey sold 9,250 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total value of $1,286,027.50. Following the sale, the director now directly owns 9,250 shares of the company’s stock, valued at approximately $1,286,027.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the sale, the director now directly owns 69,424 shares in the company, valued at $9,061,220.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,233 shares of company stock worth $6,268,259. Insiders own 0.95% of the company’s stock.

Shares of Celgene Corporation (NASDAQ CELG) traded down 0.14% on Thursday, reaching $142.77. The company’s stock had a trading volume of 983,425 shares. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $144.59. The company has a market cap of $111.70 billion, a P/E ratio of 44.21 and a beta of 1.89. The company’s 50 day moving average price is $135.45 and its 200 day moving average price is $127.81.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s revenue was up 18.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.44 EPS. Analysts forecast that Celgene Corporation will post $7.32 EPS for the current fiscal year.

A number of equities analysts have issued reports on CELG shares. Leerink Swann upgraded Celgene Corporation from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $94.42 to $150.00 in a report on Friday, June 16th. They noted that the move was a valuation call. William Blair reaffirmed an “outperform” rating on shares of Celgene Corporation in a research report on Monday, June 26th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene Corporation in a research report on Monday, August 28th. BTIG Research lowered Celgene Corporation from a “buy” rating to a “neutral” rating and raised their price target for the stock from $96.93 to $131.70 in a research report on Friday, June 30th. Finally, BidaskClub raised Celgene Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company. Celgene Corporation currently has a consensus rating of “Buy” and an average target price of $149.42.

WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/28/celgene-corporation-celg-shares-bought-by-chesley-taft-associates-llc.html.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.